ANDA 78583, held by Apotex. Aripiprazole.
As of Nov 16, 2026, ANDA 78583 (Aripiprazole), held by Apotex, was first approved by FDA on Jul 24, 2015, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 24, 2015 | Original application | Approved | None posted |
| Aripiprazole2MG · tablet;oral | Aripiprazole | Discontinued |
| Aripiprazole5MG · tablet;oral | Aripiprazole | Discontinued |
| Aripiprazole10MG · tablet;oral | Aripiprazole | Discontinued |
| Aripiprazole15MG · tablet;oral | Aripiprazole | Discontinued |
| Aripiprazole20MG · tablet;oral | Aripiprazole | Discontinued |
| Aripiprazole30MG · tablet;oral | Aripiprazole | Discontinued |
| Dec 16, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 16, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Dec 16, 2022 | Supplement 4Labeling · Standard review | Approved | None posted |
| Dec 16, 2022 | Supplement 5Labeling · Standard review | Approved | None posted |
| Dec 16, 2022 | Supplement 11Labeling · Standard review | Approved | None posted |
| Dec 16, 2022 | Supplement 12Labeling · Standard review | Approved | None posted |
| Dec 16, 2022 | Supplement 13Labeling · Standard review | Approved | None posted |
| Jul 24, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters